- Title
- Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition
- Creator
- Islam, Saiful; Rahaman, Muhammed H.; Yu, Mingfeng; Noll, Benjamin; Martin, Jennifer H.; Wang, Shudong; Head, Richard
- Relation
- Cancers Vol. 15, Issue 4, no. 1044
- Publisher Link
- http://dx.doi.org/10.3390/cancers15041044
- Publisher
- MDPI AG
- Resource Type
- journal article
- Date
- 2023
- Description
- Acute myeloid leukaemia (AML) affects predominantly elderly people and has an incidence of 1% of all cancers and 2% of all cancer deaths. Despite using intensive chemotherapy and allogeneic stem cell transplantation, the treatment options for AML remain open for innovation. Thus, there is a need to explore alternative therapies such as less toxic targeted therapies in AML. Aurora A kinase is a well-established target for the treatment of various cancers, including AML. This kinase plays a pivotal role in the cell-division cycle, particularly in different stages of mitosis, and is also involved in many other cellular regulatory processes. In a previous study, we demonstrated that the anti-viral drug rilpivirine is an Aurora A kinase inhibitor. In the current study, we have further explored the selectivity of rilpivirine for Aurora A kinase inhibition by testing this drug against a panel of 429 kinases. Concurrently, we demonstrated that rilpivirine significantly inhibited the proliferation of AML cells in a time- and concentration-dependent manner that was preceded by G2/M cell-cycle arrest leading to the induction of apoptosis. Consistent with its kinase inhibitory role, rilpivirine modulated the expression of critical proteins in the Aurora A kinase-signalling pathway. Importantly, orally administered rilpivirine significantly inhibited tumour growth in an HL-60 xenograft model without showing body weight changes or other clinical signs of toxicity. Furthermore, rilpivirine enhanced the anti-proliferative efficacy of the conventional anti-leukaemic chemotherapeutic agent cytarabine. Collectively, these findings provide the stimulus to explore further the anti-leukaemic activity of the anti-viral drug rilpivirine.
- Subject
- repurposing; rilpivirine; targeted therapy; Aurora A kinase; cancer; leukaemia; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1485579
- Identifier
- uon:51640
- Identifier
- ISSN:2072-6694
- Language
- eng
- Reviewed
- Hits: 2068
- Visitors: 2053
- Downloads: 0
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format |
|---|